Development of Epigenetic Targeted Therapies in Hematological Malignancies: From Serendipity to Synthetic Lethality

Thomas Prebet, Steven D. Gore

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Hematological malignancies are the group of disease for which epigenetic targeted agents have shown the more striking benefits. Demethylating agents are considered standard of care for acute myeloid leukemia and myelodysplastic syndromes, and several histone deacetylase inhibitors are registered for the treatment of cutaneous T-cell lymphomas. In this chapter, we will describe the clinical development of these agents focusing on success and limitations and outline the preliminary results of the next generation of epidrugs targeting epigenetic regulator genes alteration rather than the epigenetic marks by itself.

Original languageEnglish (US)
Title of host publicationEpigenetic Cancer Therapy
PublisherElsevier Inc.
Pages169-187
Number of pages19
ISBN (Electronic)9780128002247
ISBN (Print)9780128002063
DOIs
StatePublished - Jul 22 2015

Keywords

  • Histone deacetylase inhibitors
  • Hypomethylating agent
  • Leukemia
  • Lymphoma
  • Myelodysplasia

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Development of Epigenetic Targeted Therapies in Hematological Malignancies: From Serendipity to Synthetic Lethality'. Together they form a unique fingerprint.

Cite this